Cytogenetics in multiple myeloma patients progressing into extramedullary disease

Extramedullary disease in multiple myeloma patients is an uncommon event occurring either at the time of diagnosis, or during disease progression/relapse. This manifestation is frequently associated with poor outcome and resistance to treatment. We evaluated chromosomal alterations of plasma cells of multiple myeloma patients with extramedullary relapse, either in the bone marrow (BM) or at extramedullary sites, and in previous BM collection by interphase fluorescence in situ hybridization.

[1]  N. Munshi,et al.  Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide–bortezomib combinations , 2015, British journal of haematology.

[2]  L. Qiu,et al.  Features of extramedullary disease of multiple myeloma: high frequency of p53 deletion and poor survival: a retrospective single-center study of 834 cases. , 2015, Clinical lymphoma, myeloma & leukemia.

[3]  P. Liu,et al.  Extramedullary Manifestation in Multiple Myeloma Bears High Incidence of Poor Cytogenetic Aberration and Novel Agents Resistance , 2015, BioMed research international.

[4]  S. Ševčíková,et al.  Extramedullary relapse of multiple myeloma defined as the highest risk group based on deregulated gene expression data. , 2015, Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia.

[5]  Sang Hyuk Park,et al.  The t(11;14)(q13;q32) translocation as a poor prognostic parameter for autologous stem cell transplantation in myeloma patients with extramedullary plasmacytoma. , 2015, Clinical lymphoma, myeloma & leukemia.

[6]  C. Nanni,et al.  Positron emission tomography with computed tomography-based diagnosis of massive extramedullary progression in a patient with high-risk multiple myeloma. , 2014, Clinical lymphoma, myeloma & leukemia.

[7]  S. Ševčíková,et al.  Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse , 2014, Haematologica.

[8]  J. Bladé,et al.  Extramedullary Myeloma Spread Triggered by Surgical Procedures: An Emerging Entity? , 2014, Acta Haematologica.

[9]  F. Zhan,et al.  Chromosome 1q21 gains confer inferior outcomes in multiple myeloma treated with bortezomib but copy number variation and percentage of plasma cells involved have no additional prognostic value , 2013, Haematologica.

[10]  M. Tiemann,et al.  Cytogenetics of extramedullary manifestations in multiple myeloma , 2013, British journal of haematology.

[11]  H. Goldschmidt,et al.  Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project , 2013, Leukemia.

[12]  B. Barlogie,et al.  Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents , 2012, Haematologica.

[13]  J. Carpten,et al.  Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides. , 2012, Blood.

[14]  P. Sonneveld,et al.  Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders , 2012, Haematologica.

[15]  M. Tiemann,et al.  Similar incidences of TP53 deletions in extramedullary organ infiltrations, soft tissue and osteolyses of patients with multiple myeloma. , 2012, Anticancer research.

[16]  R. Hájek,et al.  Complex karyotype and translocation t(4;14) define patients with high-risk newly diagnosed multiple myeloma: results of CMG2002 trial , 2012, Leukemia & lymphoma.

[17]  R. Kyle.  Targeted therapy of multiple myeloma , 2012, Hematology.

[18]  E. Haralambieva,et al.  Features of extramedullary myeloma relapse: high proliferation, minimal marrow involvement, adverse cytogenetics: a retrospective single-center study of 24 cases , 2012, Annals of Hematology.

[19]  R. Fanin,et al.  Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. , 2011, Blood.

[20]  J. Bladé,et al.  Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  R. de Tute,et al.  Defining IgM multiple myeloma , 2011, American journal of hematology.

[22]  A. Dispenzieri,et al.  Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma , 2011, Leukemia.

[23]  J. Michálek,et al.  Optimization of immunomagnetic selection of myeloma cells from bone marrow using magnetic activated cell sorting , 2010, International journal of hematology.

[24]  T. Flores,et al.  P53 deletion may drive the clinical evolution and treatment response in multiple myeloma , 2010, European journal of haematology.

[25]  T. Buchler,et al.  Gain of 1q21 is an unfavorable genetic prognostic factor for multiple myeloma patients treated with high-dose chemotherapy. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[26]  C. Pascutto,et al.  Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[27]  Shaji K. Kumar,et al.  Review: extramedullary disease in multiple myeloma. , 2009, Clinical advances in hematology & oncology : H&O.

[28]  Hong Chang,et al.  p53 nuclear accumulation is associated with extramedullary progression of multiple myeloma. , 2009, Leukemia research.

[29]  B. Barlogie,et al.  International Myeloma Working Group molecular classification of multiple myeloma: spotlight review , 2009, Leukemia.

[30]  M. Kersten,et al.  Extramedullary relapses after allogeneic non-myeloablative stem cell transplantation in multiple myeloma patients do not negatively affect treatment outcome , 2008, Bone Marrow Transplantation.

[31]  G. Ott,et al.  Primary extramedullary plasmacytoma: similarities with and differences from multiple myeloma revealed by interphase cytogenetics , 2008, Haematologica.

[32]  K. Rezvani,et al.  Plasmacytoma relapses in the absence of systemic progression post‐high‐dose therapy for multiple myeloma , 2005, European Journal of Haematology.

[33]  G. Ott,et al.  Primary extramedullary plasmacytoma and multiple myeloma: phenotypic differences revealed by immunohistochemical analysis , 2005, The Journal of pathology.

[34]  J. Finke,et al.  Extramedullary vs medullary relapse after autologous or allogeneic hematopoietic stem cell transplantation (HSCT) in multiple myeloma (MM) and its correlation to clinical outcome , 2004, Bone Marrow Transplantation.

[35]  R. Fonseca,et al.  The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma. , 2003, Blood.

[36]  P. L. Bergsagel,et al.  Multiple myeloma: evolving genetic events and host interactions , 2002, Nature Reviews Cancer.

[37]  S. Ševčíková,et al.  [Implication of bone marrow microenvironment in pathogenesis of multiple myeloma]. , 2012, Klinicka onkologie.

[38]  J. San Miguel,et al.  Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma , 2008, Leukemia.

[39]  H. Johnsen,et al.  Possible roles for activating RAS mutations in the MGUS to MM transition and in the intramedullary to extramedullary transition in some plasma cell tumors. , 2005, Blood.

[40]  J. Renau‐Piqueras,et al.  Extramedullary multiple myeloma , 1982, Virchows Archiv. B, Cell pathology including molecular pathology.

[41]  O. Cope,et al.  Multiple myeloma. , 1948, The New England journal of medicine.